Hepatitis E Infection (Fulminant Hepatitis in Pregnancy)

Overview

Plain-Language Overview

Hepatitis E Infection (Fulminant Hepatitis in Pregnancy) is a serious liver infection caused by the Hepatitis E virus (HEV), which primarily affects the liver, an organ essential for filtering toxins and producing important proteins. This condition is especially dangerous during pregnancy, where it can lead to sudden and severe liver failure known as fulminant hepatitis. Symptoms often include jaundice, fatigue, nausea, and abdominal pain. The infection spreads mainly through contaminated water or food, affecting the digestive system before damaging the liver. Pregnant women are at higher risk of complications, which can threaten both maternal and fetal health. Early recognition of symptoms is critical due to the rapid progression and severity of the disease.

Clinical Definition

Hepatitis E Infection (Fulminant Hepatitis in Pregnancy) is an acute viral hepatitis caused by the Hepatitis E virus (HEV), a non-enveloped, single-stranded RNA virus transmitted primarily via the fecal-oral route. The infection targets hepatocytes, leading to acute liver inflammation and necrosis. In pregnant women, especially during the third trimester, the disease can progress to fulminant hepatic failure, characterized by massive hepatic necrosis, coagulopathy, encephalopathy, and multi-organ dysfunction. The pathogenesis involves a heightened immune response and possible hormonal influences that exacerbate liver injury. This condition carries a high maternal mortality rate and increased risk of adverse fetal outcomes such as miscarriage, stillbirth, or preterm delivery. Diagnosis is critical due to the rapid clinical deterioration and need for intensive supportive care.

Inciting Event

Fecal-oral transmission of Hepatitis E virus via contaminated water or food
Ingestion of undercooked animal products harboring HEV
Outbreaks in endemic regions often linked to poor sanitation
Vertical transmission from mother to fetus in severe cases

Latency Period

Incubation period of 2 to 8 weeks after HEV exposure before symptom onset
Symptoms typically develop within 3 to 6 weeks post-infection
Fulminant hepatitis may progress rapidly within days to weeks after initial symptoms

Diagnostic Delay

Nonspecific early symptoms such as malaise and anorexia delay suspicion of hepatitis E
Overlap with other viral hepatitis infections complicates diagnosis
Limited availability of HEV-specific serologic testing in endemic areas
Misattribution of symptoms to pregnancy-related nausea or cholestasis
Lack of awareness of fulminant hepatitis risk in pregnant women

Clinical Presentation

Signs & Symptoms

Acute onset jaundice with dark urine and pale stools.
Right upper quadrant abdominal pain and tenderness.
Nausea, vomiting, and anorexia as systemic symptoms of hepatitis.
Fatigue and malaise reflecting systemic illness.
Rapid progression to hepatic encephalopathy in fulminant cases, especially in pregnancy.

History of Present Illness

Prodromal phase with fatigue, anorexia, nausea, and low-grade fever
Development of jaundice, dark urine, and pale stools indicating cholestasis
Right upper quadrant abdominal pain and hepatomegaly
Rapid progression to encephalopathy, coagulopathy, and ascites in fulminant cases
Symptoms worsen particularly in the third trimester of pregnancy

Past Medical History

History of exposure to contaminated water or travel to endemic areas
Previous episodes of viral hepatitis or liver disease
No specific chronic conditions are required but immunosuppression may worsen course
Lack of prior hepatitis E vaccination or immunity

Family History

No known heritable predisposition to hepatitis E infection
No familial syndromes associated with increased risk of fulminant hepatitis E
Family members may share environmental exposure risks in endemic areas
No genetic mutations linked to increased severity of HEV infection

Physical Exam Findings

Jaundice with yellowing of the sclera and skin due to elevated bilirubin.
Hepatomegaly with a tender, enlarged liver on palpation.
Ascites indicating portal hypertension or liver failure.
Encephalopathy signs such as asterixis or altered mental status in fulminant cases.
Petechiae or ecchymoses due to coagulopathy from liver dysfunction.

Diagnostic Workup

Diagnostic Criteria

Diagnosis of hepatitis E infection relies on detecting anti-HEV IgM antibodies in serum, which indicate recent infection. Confirmation is achieved by identifying HEV RNA through PCR testing in blood or stool samples. Clinical diagnosis includes evidence of acute hepatitis with elevated liver enzymes (AST and ALT), jaundice, and symptoms consistent with liver failure in a pregnant patient. Fulminant hepatitis is defined by the rapid onset of hepatic encephalopathy and coagulopathy within weeks of symptom onset. Exclusion of other causes of acute liver failure, such as hepatitis A, B, C, and drug-induced liver injury, is essential for accurate diagnosis.

Pathophysiology

Key Mechanisms

Hepatocellular necrosis caused by direct cytopathic effect of Hepatitis E virus (HEV) infection
Immune-mediated liver injury due to heightened maternal immune response during pregnancy
Fulminant hepatic failure resulting from massive hepatocyte loss and impaired liver regeneration
Coagulopathy from decreased synthesis of clotting factors in the damaged liver
Acute liver inflammation with elevated transaminases and bilirubin due to viral replication and immune activation

Involvement	Details
Organs	Liver is the central organ involved in hepatitis E infection, with fulminant hepatitis causing acute liver failure and systemic complications.
Organs	Placenta may be involved in vertical transmission and contributes to the increased severity of hepatitis E during pregnancy.
Tissues	Liver parenchyma is the main tissue affected by HEV, showing hepatocellular necrosis and inflammation in fulminant hepatitis.
Cells	Hepatocytes are the primary target cells of HEV, undergoing viral replication and injury leading to liver dysfunction.
	Kupffer cells mediate the innate immune response and contribute to hepatic inflammation in hepatitis E infection.
	T lymphocytes participate in the adaptive immune response, contributing to viral clearance and immunopathology.
Chemical Mediators	Interferon-gamma is produced by activated T cells and plays a key role in antiviral defense against HEV.
	Tumor necrosis factor-alpha (TNF-α) contributes to hepatic inflammation and hepatocyte apoptosis in fulminant hepatitis.
	Interleukin-6 (IL-6) is elevated during acute infection and correlates with systemic inflammatory response and liver injury.

Treatments

Pharmacological Treatments

Non-pharmacological Treatments

Provide intensive supportive care including fluid and electrolyte management to maintain hemodynamic stability.
Administer vitamin K to correct coagulopathy associated with fulminant hepatitis.
Consider liver transplantation evaluation in cases of severe acute liver failure unresponsive to supportive measures.
Monitor and manage complications such as hepatic encephalopathy with lactulose and rifaximin.

Prevention

Pharmacological Prevention

No widely available specific antiviral therapy for hepatitis E.
HEV vaccine licensed in China but not globally available for routine use.

Non-pharmacological Prevention

Avoidance of contaminated water and improved sanitation to prevent fecal-oral transmission.
Proper hand hygiene especially in endemic areas.
Safe food practices including thorough cooking of pork and game meat.
Screening of blood products in endemic regions to prevent transfusion-related transmission.

Outcome & Complications

Complications

Fulminant hepatic failure with coagulopathy and encephalopathy.
Acute kidney injury secondary to hepatorenal syndrome.
Disseminated intravascular coagulation (DIC) due to severe liver dysfunction.
Preterm labor and fetal loss in pregnant women.
Cholestasis and severe hepatic inflammation.

Short-term Sequelae	Long-term Sequelae
Acute liver failure requiring intensive supportive care. Hepatic encephalopathy with altered consciousness and coma. Coagulopathy leading to bleeding complications. Multi-organ failure in severe fulminant hepatitis.	Complete recovery is common if acute liver failure is survived. Chronic liver disease is rare as hepatitis E usually does not cause chronic infection. Post-hepatitis fatigue syndrome may persist for weeks to months.

Differential Diagnoses

Hepatitis E Infection (Fulminant Hepatitis in Pregnancy) versus Acute Hepatitis B Infection

Hepatitis E Infection (Fulminant Hepatitis in Pregnancy)	Acute Hepatitis B Infection
Infection with hepatitis E virus, an RNA virus	Infection with hepatitis B virus, a DNA virus
Transmission mainly via fecal-oral route through contaminated water	Transmission primarily via blood and sexual contact
Positive anti-HEV IgM antibodies	Positive hepatitis B surface antigen (HBsAg) and IgM anti-HBc
High risk of fulminant hepatitis especially in third trimester pregnancy	Lower risk of fulminant hepatitis in pregnancy

Hepatitis E Infection (Fulminant Hepatitis in Pregnancy) versus Acute Hepatitis A Infection

Hepatitis E Infection (Fulminant Hepatitis in Pregnancy)	Acute Hepatitis A Infection
Infection with hepatitis E virus, a hepevirus	Infection with hepatitis A virus, a picornavirus
Fecal-oral transmission often linked to contaminated water	Fecal-oral transmission often linked to contaminated food
Common cause of fulminant hepatitis in pregnancy	Rarely causes fulminant hepatitis in pregnancy
Positive anti-HEV IgM antibodies	Positive anti-HAV IgM antibodies

Hepatitis E Infection (Fulminant Hepatitis in Pregnancy) versus Autoimmune Hepatitis

Hepatitis E Infection (Fulminant Hepatitis in Pregnancy)	Autoimmune Hepatitis
Absence of autoantibodies, presence of viral markers	Elevated serum autoantibodies such as ANA and anti-smooth muscle antibody
Acute, often self-limited or fulminant course	Chronic progressive liver inflammation with fluctuating course
No role for immunosuppression; supportive care only	Improves with immunosuppressive therapy

Hepatitis E Infection (Fulminant Hepatitis in Pregnancy) versus Wilson Disease

Hepatitis E Infection (Fulminant Hepatitis in Pregnancy)	Wilson Disease
Can affect all ages but fulminant hepatitis in pregnancy occurs in adults	Typically presents in adolescents or young adults
Normal ceruloplasmin and no copper accumulation	Low serum ceruloplasmin and elevated 24-hour urinary copper
No copper accumulation or Kayser-Fleischer rings	Hepatic copper accumulation with Kayser-Fleischer rings

Hepatitis E Infection (Fulminant Hepatitis in Pregnancy) versus Drug-Induced Liver Injury (DILI)

Hepatitis E Infection (Fulminant Hepatitis in Pregnancy)	Drug-Induced Liver Injury (DILI)
No recent hepatotoxic drug exposure; history of exposure to contaminated water	Recent use of hepatotoxic drugs or supplements
Incubation period of 2-8 weeks after fecal-oral exposure	Variable onset from days to weeks after drug exposure
Predominantly hepatocellular injury with elevated transaminases	Mixed hepatocellular and cholestatic injury pattern depending on drug